Étiquette : suicide

Bibliographie : Kétamine, Dr Christian Sueur, GRECC, mai 2021

Bibliographie : Kétamine Dr Christian Sueur, GRECC, (mai 2021)   Kétamine en Psychiatrie : 1 - 3 Usages thérapeutiques en médecine psychédélique : 4 Kétamine et psychose : 5 - 6 Kétamine et traitement de la dépression : 7 - 20 Kétamine et prise en charge de l’idéation suicidaire : 21 - 22 Kétamine et traitement de la dépression chez les enfants et adolescents : 23 - 24 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) : 25 - 27 Ketamine et addictions : 28 - 29 Kétamine et sevrage des opiacés : 30 Kétamine et prise en charge de la douleur : 31 - 32 Kétamine et prise en charge de [...]

Lire la suite

High-Potency Cannabis Products Linked to Suicidality, Doug Brunk, Medscape.com, February 22, 2021

High-Potency Cannabis Products Linked to Suicidality Doug Brunk Medscape Medical News © 2021 WebMD, LLC February 22, 2021 Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. In the days since recreational sales of marijuana became legal in Colorado in January 2014, concerning trends have emerged among the state's young cannabis users. Dr Paula Riggs According to a report from the Rocky Mountain High Intensity Drug Trafficking Area, between 2014 and 2017, the number of suicides positive for marijuana increased 250% among those aged 10-19 years (from 4 to 14) and 22% among those aged 20 and older (from 118 to 144). "Other states are seeing something [...]

Lire la suite

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation : A Systematic Review and Individual Participant Data Meta-Analysis, Samuel T. Wilkinson et al., 2018

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis Samuel T. Wilkinson, M.D., Elizabeth D. Ballard, Ph.D., Michael H. Bloch, M.D., M.S., Sanjay J. Mathew, M.D., James W. Murrough, M.D., Ph.D., Adriana Feder, M.D., Peter Sos, M.D., Ph.D., Gang Wang, M.D., Carlos A. Zarate, Jr., M.D., Gerard Sanacora, M.D., Ph.D. American Journal of Psychiatry, 2018, 175, (2) 150–158. Doi : 10.1176/appi.ajp.2017.17040472   Objective : Suicide is a public health crisis with limited treatment options. The authors conducted a systematic review and individual participant data meta-analysis examining the effects of a single dose of ketamine [...]

Lire la suite

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial, Richard J. Zeifman et al., 2019

The Impact of Ayahuasca on Suicidality : Results From a Randomized Controlled Trial Richard J. Zeifman, Fernanda Palhano-Fontes, Jaime Hallak, Emerson Arcoverde, João Paulo Maia-Oliveira, Draulio B. Araujo Frontiers in Pharmacology, 2019, Volume 10, Article 1325, 1-10. doi : 10.3389/fphar.2019.01325   Suicide is a major public health problem. Given increasing suicide rates and limitations surrounding current interventions, there is an urgent need for innovative interventions for suicidality. Although ayahuasca has been shown to target mental health concerns associated with suicidality (i.e., depression and hopelessness), research has not yet explored the impact of ayahuasca on suicidality. Therefore, we conducted secondary analyses of a randomized placebo-controlled trial in [...]

Lire la suite

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women, Elena Argento et al., 2018

The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women Elena Argento, Melissa Braschel, Zach Walsh, M. Eugenia Socias and Kate Shannon Journal of Psychopharmacology, 2018, 1–7 DOI : 10.1177/0269881118798610   Abstract Background/aims : Given high rates of depression and suicide among marginalized women, and increasing calls to integrate trauma-informed biomedical and community-led structural interventions, this study longitudinally examines the potential moderating effect of psychedelic use on the relationship between other illicit drug use and suicide risk. Methods : Data (2010–2017) were drawn from a community-based, prospective open cohort of marginalized women in Vancouver, Canada. Extended Cox regression [...]

Lire la suite

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences, Theresa M. Carbonaro et al., 2016

Survey study of challenging experiences after ingesting psilocybin mushrooms : Acute and enduring positive and negative consequences Theresa M. Carbonaro, Matthew P. Bradstreet, Frederick S. Barrett, Katherine A. MacLean, Robert Jesse, Matthew W. Johnson and Roland R. Griffiths Journal of Psychopharmacology, 2016, 1 –11 DOI: 10.1177/0269881116662634 Abstract Acute and enduring adverse effects of psilocybin have been reported anecdotally, but have not been well characterized. For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming psilocybin mushrooms. Thirty-nine percent rated it among the top five most challenging [...]

Lire la suite

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study, Carla M. Canuso et al., 2018,

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Carla M. Canuso, M.D., Jaskaran B. Singh, M.D., Maggie Fedgchin, Pharm.D., Larry Alphs, M.D., Ph.D., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Pinter, M.S., David Hough, M.D., Gerard Sanacora, M.D., Ph.D., Husseini Manji, M.D., Wayne C. Drevets, M.D. American Journal of Psychiatry, 2018, 175, 620–630 doi: 10.1176/appi.ajp.2018.17060720   Objective : The authors compared the efficacy of standardof- care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among [...]

Lire la suite

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, P.S. Hendricks et al., 2015

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population Peter S Hendricks, Christopher B Thorne, C Brendan Clark, David W Coombs, and Matthew W Johnson Journal of Psychopharmacology · January 2015 DOI: 10.1177/0269881114565653 ·   Abstract : Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA [...]

Lire la suite